Afficher la couverture 'Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers | El-Botty, Rania' en grand format
/5

0 avis

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers

Archive ouverte

El-Botty, Rania | Morriset, Ludivine | Montaudon, Elodie | Tariq, Zakia | Schnitzler, Anne | Bacci, Marina | Lorito, Nicla | Sourd, Laura | Huguet, Léa | Dahmani, Ahmed | Painsec, Pierre | Derrien, Heloise | Vacher, Sophie | Masliah-Planchon, Julien | Raynal, Virginie | Baulande, Sylvain | Larcher, Thibaut | Vincent-Salomon, Anne | Dutertre, Guillaume | Cottu, Paul | Gentric, Géraldine | Mechta-Grigoriou, Fatima | Hutton, Scott | Driouch, Keltouma | Bièche, Ivan | Morandi, Andrea | Marangoni, Elisabetta

Edité par CCSD ; Nature Publishing Group -

International audience. Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients' tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell lines we demonstrate that a fraction of metastatic ER + BC is highly reliant on oxidative phosphorylation (OXPHOS). Treatment by the OXPHOS inhibitor IACS-010759 strongly inhibits tumour growth in multiple endocrine and palbociclib resistant PDX. Mutations in the PIK3CA/AKT1 genes are significantly associated with response to IACS-010759. At the metabolic level, in vivo response to IACS-010759 is associated with decreased levels of metabolites of the glutathione, glycogen and pentose phosphate pathways in treated tumours. In vitro, endocrine and palbociclib resistant cells show increased OXPHOS dependency and increased ROS levels upon IACS-010759 treatment. Finally, in ER + BC patients, high expression of OXPHOS associated genes predict poor prognosis. In conclusion, these results identify OXPHOS as a promising target for treatment resistant ER + BC patients.

Suggestions

Du même auteur

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance

Archive ouverte | Montaudon, Elodie | CCSD

International audience. A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC) develop resistance to endocrine treatments (ET) and relapse with metastatic disease. Here we per...

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers

Archive ouverte | ter Brugge, Petra | CCSD

International audience. The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer (TNBC), however, the existing met...

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

Archive ouverte | Coussy, Florence | CCSD

Topoisomerase I (TOP1) inhibitors trap TOP1 cleavage complexes resulting in DNA double-strand breaks (DSBs) during replication, which are repaired by homologous recombination (HR). Triple-negative breast cancer (TNBC) could be eli...

Chargement des enrichissements...